• 1
    Cloyd JC, Remmel RP. Antiepileptic drug pharmacokinetics and interactions: impact on treatment of epilepsy. Pharmacotherapy 2000;20: 139S51S.
  • 2
    French JA, Gidal BE. Antiepileptic drug interactions. Epilepsia 2000;41: S306.
  • 3
    Perucca E, Dulac O, Shorvon S, et al. Harnessing the clinical potential of antiepileptic drug therapy: dosage optimization. CNS Drugs 2001;15: 60921.
  • 4
    Swann AC. Major system toxicities and side effects of anticonvulsants. J Clin Psychiatry 2001;62: 1621.
  • 5
    Hauser WA, Kurland LT. The epidemiology of epilepsy in Rochester, MInnesota, 1935 through 1967. Epilepsia 1975;16: 166.
  • 6
    Hauser WA, Hersdorffer DC. Epilepsy: frequency, causes and consequences. New York: Demos, 1990.
  • 7
    Hauser WA. Status epilepticus: epidemiologic considerations. Neurology 1990;40: 913.
  • 8
    Eder HG, Jones DB, Fisher RS. Local perfusion of diazepam attenuates interictal and ictal events in the bicuculline model of epilepsy in rats. Epilepsia 1997;38: 51621.
  • 9
    Stein AG, Eder HG, Blum DE, et al. An automated drug delivery system for focal epilepsy. Epilepsy Res 2000;39: 10314.
  • 10
    Graber KD, Prince DA. Tetrodotoxin prevents posttraumatic epileptogenesis in rats. Ann Neurol 1999;46: 23442.
  • 11
    Kubek AJ, Liang D, Byrd KE, et al. Prolonged seizure suppression by a single implantable polymeric-TRH microdisk preparation. Brain Res 1998;809: 18997.
  • 12
    Tamargo RJ, Rossell LA, Kossoff EH, et al. The intracerebral administration of phenytoin using controlled-release polymers reduces experimental seizures in rats. Epilepsy Res 2002;48: 14555.
  • 13
    Kohane DS, Lipp M, Kinney R, et al. Sciatic nerve blockade with lipid-protein-sugar particles containing bupivacaine. Pharm Res 2000;17: 12439.
  • 14
    Kohane DS, Plesnila N, Thomas SS, et al. Lipid-sugar particles for intracranial drug delivery: safety and biocompatibility. Brain Res 2002;946: 20613.
  • 15
    Kohane DS, Lipp M, Kinney R, et al. Biocompatibility of lipid-protein-sugar particles containing bupivacaine in the epineurium. J Biomed Mater Res 2002;59: 4509.
  • 16
    Turski L, Ikonomidou C, Turski WA, et al. Review: cholinergic mechanisms and epileptogenesis: the seizures induced by pilocarpine: a novel experimental model of intractable epilepsy. Synapse 1989;3: 15471.
  • 17
    Millan M, Chapman AG, Meldrum BS. Extracellular amino acid levels in hippocampus during pilocarpine-induced seizures. Epilepsy Res 1993;14: 13948.
  • 18
    Isokawa M, Mello LE. NMDA receptor-mediated excitability in dendritically deformed dentate granule cells in pilocarpine-treated rats. Neurosci Lett 1991;129: 6973.
  • 19
    Collins RC. Anticonvulsant effects of muscimol. Neurology 1980;30: 57581.
  • 20
    Cavalheiro EA, Czuzwar SJ, Kleinrok S. Intracerebral cholinomimetics produce seizure-related brain damage in rats. Br J Pharmacol 1983;79: 284P.
  • 21
    Paxinos G, Watson C. The rat brain in stereotaxic coordinates. 4th ed. San Diego: Academic Press, 1998.
  • 22
    Holmes GL, Gaiarsa JL, Chevassus-Au-Louis N, et al. Consequences of neonatal seizures in the rat: morphological and behavioral effect. Ann Neurol 1998;44: 84557.
  • 23
    Holmes GL, Sarkisian M, Ben-Ari Y, et al. Mossy fiber sprouting following recurrent seizures during early development in rats. J Comp Neurol 1999;404: 53753.
  • 24
    Mikati MA, Holmes GL, Chronopoulos A, et al. Phenobarbital modifies seizure-related brain injury in the developing brain. Ann Neurol 1994;36: 42533.
  • 25
    Sokal RR, Rohlf FJ. Biometry: the principles and practice of statistics in biological research. 3rd ed. New York: WH Freeman, 1995: 498524.
  • 26
    Montgomery DC. Design and analysis of experiments. 5th ed. New York: John Wiley & Sons, 2001: 96104.
  • 27
    Langer R. Drug delivery and targeting. Nature 1998;392: 510.
  • 28
    Ben-Jebria A, Chen D, Eskew ML, et al. Large porous particles for sustained protection from carbachol-induced bronchoconstriction in guinea pigs. Pharm Res 1999;16: 55561.